



These Were the Top 5 Venture Capital Deals in Houston in 2021

December 27, 2021 1:00 PM EST



Cancer-Fighting Company Based in Houston Emerges from Stealth and Snags \$74M in its Latest Round

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its \$74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team." [Click here to read the full article](#)

SOURCE:

[InnovationMap, by Natalie Harms](#)